{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:55:36Z","timestamp":1791042936004,"version":"4.1.0"},"reference-count":85,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp;amp; Translational All"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aspirin\u2010exacerbated respiratory disease (AERD), also termed nonsteroidal anti\u2010inflammatory drug exacerbated respiratory disease (NERD), is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase\u20101 inhibitors, frequently resulting in severe, treatment\u2010refractory airway disease. Biologic therapies targeting type 2 inflammation are increasingly used in AERD; though their relative efficacy remains incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a semi\u2010systematic narrative review of biologic therapies in AERD, guided by established narrative review frameworks. PubMed\/Medline, ScienceDirect, and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      were searched for studies reporting clinical outcomes in AERD\/NERD or clearly defined AERD\/NERD subgroups. This review synthesizes current evidence and presents an evidence\u2010informed clinical framework to support biologic selection in patients with AERD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen studies identified, including randomized controlled trials, observational studies, and real\u2010world studies. Across these studies, dupilumab was most consistently associated with improvements in both upper and lower airway outcomes. Anti\u2013IL\u20105 and anti\u2013IL\u20105R\u03b1 therapies reduced eosinophilia and asthma exacerbations, with variable sinonasal benefit. Omalizumab demonstrated efficacy in selected atopic phenotypes and in conjunction with aspirin therapy following desensitization. Emerging subgroup data suggests that Tezepelumab may reduce asthma exacerbations in AERD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence suggests biologic therapies provide meaningful benefit in AERD, although available evidence is limited by small sample sizes and heterogeneous designs. Prospective comparative studies are needed to inform optimal biologic selection and sequencing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/clt2.70212","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:29:56Z","timestamp":1791041396000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3263-2897","authenticated-orcid":false,"given":"Jennifer K.","family":"Priessnitz","sequence":"first","affiliation":[{"name":"Division of Internal Medicine Macon &amp; Joan Brock Virginia Health Sciences at Old Dominion University  Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6178-1377","authenticated-orcid":false,"given":"Anastasia","family":"Hagopian","sequence":"additional","affiliation":[{"name":"Department of Medicine Eastern Virginia Medical School at Old Dominion University  Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-0259","authenticated-orcid":false,"given":"Alison J.","family":"Patev","sequence":"additional","affiliation":[{"name":"Research and Infrastructure Service Enterprise Macon &amp; Joan Brock Virginia Health Sciences at Old Dominion University  Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[{"name":"Division of Allergy Macon &amp; Joan Brock Virginia Health Sciences at Old Dominion University  Norfolk Virginia USA"},{"name":"Division of Division of Rhinology &amp; Endoscopic Sinus and Skull Base Surgery Macon &amp; Joan Brock Virginia Health Sciences at Old Dominion University  Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1835-5390","authenticated-orcid":false,"given":"Kent K.","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Allergy Macon &amp; Joan Brock Virginia Health Sciences at Old Dominion University  Norfolk Virginia USA"},{"name":"Division of Division of Rhinology &amp; Endoscopic Sinus and Skull Base Surgery Macon &amp; Joan Brock Virginia Health Sciences at Old Dominion University  Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/lio2.387"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2011.3.1.3"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.01.038"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.05.016"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.020"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2025.03.006"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/CLT2.12235"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.09.019"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.IAC.2012.11.006"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2020.11.001"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.4193\/RHIN20.600"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.13599"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.10.026"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.12.022"},{"key":"e_1_2_14_16_1","doi-asserted-by":"crossref","unstructured":"J. T.Li J.Oppenheimer I. L.Bernstein et\u00a0al. Attaining Optimal Asthma Control: A Practice Parameter.https:\/\/doi.org\/10.1016\/j.jaci.2005.08.017.","DOI":"10.1016\/j.jaci.2005.08.017"},{"key":"e_1_2_14_17_1","unstructured":"GINA 2026 Severe Asthma Guide \u2013 Now Available! \u2013 Global Initiative for Asthma \u2013 GINA. Accessed August 5 2026.https:\/\/ginasthma.org\/gina\u20102026\u2010severe\u2010asthma\u2010guide\u2010now\u2010available\/."},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906\u20101215OC"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2021.08.015"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000001051"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.04.007"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.S237463"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMRA1712125"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2023.06.028"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155884"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/FALGY.2021.734733"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.06.001"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0186\u20102025"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0899\u20103467(07)60142\u20106"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2019.40.4241"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/19458924211030486"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(19)31881\u20101"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.03.010"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAIP.2025.08.032"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.020"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.05.016"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20102600(21)00097\u20107"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010024\u201002889\u20108"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2024.102041"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202210\u20102005OC"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.09.030"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ALR.70072"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAIP.2025.07.038"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1159\/000519228"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.032"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1196\/ANNALS.1313.009"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22963"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.11.011"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S14520"},{"key":"e_1_2_14_51_1","unstructured":"Adverse Reactions CSU XOLAIR\u00ae (Omalizumab) HCP. Accessed November 10 2025.https:\/\/www.xolairhcp.com\/chronic\u2010spontaneous\u2010urticaria\/side\u2010effects\/summary.html."},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41598\u2010025\u201091463\u20105"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/NRD4624"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13954"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.08.021"},{"key":"e_1_2_14_57_1","unstructured":"Highlights of Prescribing Information. Accessed November 10 2025.www.fda.gov\/medwatch."},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2023.05.014"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.14639\/0392\u2010100X\u2010N1911"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANAI.2022.01.036"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp102"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(12)60988\u2010X"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1090972"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1403291"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/S12890\u2010024\u201002885\u20102"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAIP.2017.08.024"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.201707\u20101323OC"},{"key":"e_1_2_14_69_1","unstructured":"\u201cFull Prescribing Information: Contents* 1 Indications and Usage 2 Dosage and Administration 2.1 Dosing 2.2 Preparation and Administration Instructions 3 Dosage Forms and Strengths 4 Contraindications 5 Warnings and Precautions 5.\u201d Accessed November 10 2025.www.fda.gov\/medwatch."},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.08.004"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.030"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11684\u2010017\u20100565\u20100"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20102600(20)30414\u20108"},{"key":"e_1_2_14_74_1","unstructured":"Safety Profile \u201cFASENRA\u00ae (Benralizumab) for HCPs. Accessed November 10 2025.https:\/\/www.fasenrahcp.com\/safety."},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.S413064"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.1018"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11882\u2010025\u201001192\u2010Y"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034073"},{"key":"e_1_2_14_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CYTO.2022.156091"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.03.013"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.70458"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2012.06.025"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(25)00287\u20105"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2414482"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.01.018"}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clt2.70212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:29:58Z","timestamp":1791041398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.70212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":85,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/clt2.70212"],"URL":"https:\/\/doi.org\/10.1002\/clt2.70212","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"value":"2045-7022","type":"print"},{"value":"2045-7022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"article-number":"e70212"}}